Hans Holger Fischer

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.5K citations · Full text

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 162 citations

Breast Oncology, Medicine, Neoadjuvant Dual Blockade +8

Radiotherapy with and without cisplatin in bladder cancer

Rolf Sauer, Jürgen Dunst, A. Altendorf-Hofmann et al. · International Journal of Radiation Oncology*Biology*Physics · 1990 · 98 citations

Urology, Radiation Medicine, Radiation Therapy +4

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 80 citations · Full text

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 76 citations

Breast Oncology, Medicine, Trastuzumab Therapy +9